TimesSquare Capital Management LLC Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

TimesSquare Capital Management LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 269,121 shares of the company's stock, valued at approximately $30,752,000. TimesSquare Capital Management LLC owned 0.24% of Vaxcyte as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Riverview Trust Co purchased a new position in shares of Vaxcyte during the 3rd quarter worth $27,000. Fifth Third Bancorp purchased a new stake in Vaxcyte in the 2nd quarter valued at about $35,000. Blue Trust Inc. increased its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. J.Safra Asset Management Corp lifted its holdings in shares of Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after acquiring an additional 526 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Vaxcyte in the second quarter worth approximately $70,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PCVX shares. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Jefferies Financial Group upped their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday. Leerink Partners increased their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Finally, BTIG Research increased their price target on Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte presently has an average rating of "Buy" and an average target price of $147.50.

Vaxcyte Trading Up 3.9 %

Shares of NASDAQ:PCVX traded up $3.97 during trading on Friday, hitting $106.67. The company's stock had a trading volume of 1,014,879 shares, compared to its average volume of 809,467. Vaxcyte, Inc. has a fifty-two week low of $46.16 and a fifty-two week high of $121.06. The stock's 50-day moving average price is $111.56 and its two-hundred day moving average price is $87.42.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares in the company, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew Guggenhime sold 42,000 shares of the firm's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 117,464 shares of company stock valued at $12,640,276. Company insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.